The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone

Area of Science:

• Hematology
• Oncology
• Cell Biology

Background:

• Dexamethasone (Dex) is a common treatment for multiple myeloma, offering symptom relief but not a cure.
• Drug resistance in multiple myeloma is a significant clinical challenge, necessitating research into underlying mechanisms.
• The bone marrow microenvironment is known to influence cancer cell behavior and drug response.

Purpose of the Study:

• To investigate the role of the bone marrow microenvironment in mediating resistance to Dexamethasone in multiple myeloma.
• To determine if bone marrow stromal cells produce interleukin-6 (IL-6) that protects myeloma cells from Dexamethasone-induced apoptosis.
• To differentiate the protective effects of stroma on mature versus immature myeloma cells.

Main Methods:

• Compared IL-6 production by marrow stromal cells from myeloma patients before, during, and after Dexamethasone exposure.
• Purified myeloma cells from bone marrow using cell sorting based on CD38 and CD45 expression and light-scatter parameters.
• Co-cultured purified myeloma cells with bone marrow stromal cells to assess protection against Dexamethasone-induced apoptosis.

Main Results:

• Stromal cells continued to produce IL-6 even when exposed to Dexamethasone, although at reduced concentrations.
• Immature CD38+CD45+ myeloma cells were effectively protected from Dexamethasone-induced apoptosis by co-culture with stromal cells.
• Mature CD38+CD45- myeloma cells did not exhibit protection when co-cultured with stromal cells.

Conclusions:

• Bone marrow stromal cells, through IL-6 production, protect immature multiple myeloma cells from Dexamethasone.
• This IL-6-mediated protection likely explains the palliative efficacy of Dexamethasone and the emergence of drug resistance.
• Combining IL-6 antagonists with Dexamethasone may be a viable strategy to overcome resistance in immature myeloma cells.